{"disease":{"id":"major-depressive-disorder","name":"Major Depressive Disorder (MDD)","therapeutic_area":"Psychiatry","data":{"aiSummary":"The treatment landscape for Major Depressive Disorder (MDD) involves a variety of antidepressants, including SSRIs, SNRIs, and other agents. Recent advances include the use of esketamine for treatment-resistant depression and the development of novel agents targeting different mechanisms. The pipeline includes several new compounds, such as SAGE-217, and novel approaches, such as those from Axsome Therapeutics. The focus is on personalized treatment strategies, including pharmacogenomic testing and the use of augmentation strategies to improve outcomes.","drug_count":8,"description":"Major Depressive Disorder (MDD) is a common and serious mental illness characterized by persistent feelings of sadness, loss of interest, and other cognitive and physical symptoms. The pathophysiology of MDD is complex, involving imbalances in neurotransmitters like serotonin, norepinephrine, and dopamine, as well as structural and functional changes in the brain. Treatment typically involves a combination of pharmacotherapy and psychotherapy.","subtype_count":12},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.941Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":35,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"rexulti","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rexulti","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor","drug_class":"","quality_score":24,"revenue":"1400","mechanism":null},{"drug_id":"brexpiprazole","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rexulti","generic_name":"BREXPIPRAZOLE","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":60,"revenue":"1400","mechanism":""},{"drug_id":"desvenlafaxine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pristiq","generic_name":"desvenlafaxine","company_name":"Alembic Pharms Ltd","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin and Norepinephrine Reuptake Inhibitor","quality_score":82,"revenue":"1041.0","mechanism":"Pristiq works by blocking the reabsorption of serotonin and norepinephrine in the brain, allowing more of these neurotransmitters to be available for use."},{"drug_id":"pristiq","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pristiq","generic_name":"Desvenlafaxine Succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":75,"revenue":"1041.0","mechanism":"Potentiates serotonin and norepinephrine in CNS through reuptake inhibition."},{"drug_id":"fluoxetine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"vortioxetine","indication_name":"Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trintellix","generic_name":"vortioxetine","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor","drug_class":"Serotonin modulator and stimulator (SMS); SSRI-like agent","quality_score":78,"revenue":"800","mechanism":"Vortioxetine enhances serotonergic activity through serotonin reuptake inhibition with additional 5-HT3 antagonism and 5-HT1A agonism."},{"drug_id":"vortioxetine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trintellix","generic_name":"vortioxetine","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor","drug_class":"Serotonin modulator and stimulator (SMS); SSRI-like agent","quality_score":78,"revenue":"800","mechanism":"Vortioxetine enhances serotonergic activity through serotonin reuptake inhibition with additional 5-HT3 antagonism and 5-HT1A agonism."},{"drug_id":"olanzapine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":38,"revenue":"300","mechanism":null},{"drug_id":"dosulepin","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dothiepin","generic_name":"Dosulepin","company_name":"All India Institute of Medical Sciences, Bhubaneswar","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressants","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"levomilnacipran","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fetzima","generic_name":"LEVOMILNACIPRAN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin and Norepinephrine Reuptake Inhibitor","quality_score":64,"revenue":null,"mechanism":"Fetzima works by blocking the reabsorption of serotonin and norepinephrine in the brain, allowing more of these neurotransmitters to be available for communication between brain cells."},{"drug_id":"vilazodone","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viibryd","generic_name":"vilazodone","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 4, 5-hydroxytryptamine receptor 7","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"selegiline","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selegiline Hydrochloride","generic_name":"SELEGILINE","company_name":"Somerset","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"duloxetine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cymbalta","generic_name":"duloxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake","drug_class":"Serotonin and norepinephrine reuptake inhibitor (SNRI)","quality_score":68,"revenue":null,"mechanism":"Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms."},{"drug_id":"agomelatine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thymanax","generic_name":"AGOMELATINE","company_name":"Les Laboratoires Servier","drug_phase":"marketed","molecular_target":"Melatonin receptor type 1A","drug_class":"agomelatine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"gepirone","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEPIRONE","company_name":"","drug_phase":"marketed","molecular_target":"5HT1A receptors","drug_class":"gepirone","quality_score":53,"revenue":null,"mechanism":"EXXUA's antidepressant effect may stem from modulating serotonergic activity via selective agonist activity at 5HT1A receptors."},{"drug_id":"bupropion-sr-150mg-bid","indication_name":"Treatment of Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupropion SR 150mg bid","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Dopamine transporter (DAT), Norepinephrine transporter (NET)","drug_class":"Atypical antidepressant, Norepinephrine-dopamine reuptake inhibitor (NDRI)","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"paroxetine","indication_name":"Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paroxetine","generic_name":"paroxetine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Serotonin (5-HT) reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":73,"revenue":null,"mechanism":"Inhibits neuronal reuptake of serotonin in the central nervous system, presumed mechanism for treating psychiatric disorders."},{"drug_id":"bat","indication_name":"Treatment of major depressive disorder in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"placebp","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Placebp","generic_name":"placebp","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"None","drug_class":"Placebo","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"bupropion-immediate-release-ir","indication_name":"Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bupropion immediate release (IR)","generic_name":"bupropion-immediate-release-ir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dopamine transporter, Norepinephrine transporter","drug_class":"Norepinephrine-dopamine reuptake inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"nefazodone","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Serzone","generic_name":"NEFAZODONE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin Reuptake Inhibitor","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"mianserin","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(+/-)-Mianserin","generic_name":"MIANSERIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"mianserin","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"escitalopram","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lexapro","generic_name":"escitalopram","company_name":"Generic (originally Lundbeck/Forest)","drug_phase":"marketed","molecular_target":"Serotonin (5-HT) reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":61,"revenue":null,"mechanism":"Inhibits CNS neuronal reuptake of serotonin (5-HT), potentiating serotonergic activity."},{"drug_id":"venlafaxine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effexor","generic_name":"venlafaxine","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C","drug_class":"SNRI (Serotonin-norepinephrine reuptake inhibitor)","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"prozac","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"bupropion","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wellbutrin","generic_name":"bupropion","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"NDRI (Norepinephrine-dopamine reuptake inhibitor)","quality_score":55,"revenue":null,"mechanism":"Norepinephrine-dopamine reuptake inhibitor (NDRI) that treats depression and aids smoking cessation without serotonergic side effects."},{"drug_id":"parnate","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Parnate","company_name":"Par Pharmaceutical, Inc.","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Cytochrome P450 2B6, Lysine-specific histone demethylase 1B","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"effexor-xr","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effexor","generic_name":"Venlafaxine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake transporters","drug_class":"Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)","quality_score":70,"revenue":null,"mechanism":"Potentiates serotonin and norepinephrine in CNS through reuptake inhibition."},{"drug_id":"citalopram","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celexa","generic_name":"CITALOPRAM","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin Reuptake Inhibitor","quality_score":80,"revenue":null,"mechanism":"Celexa works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells."},{"drug_id":"tranylcypromine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parnate","generic_name":"TRANYLCYPROMINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Parnate works by blocking an enzyme that breaks down certain neurotransmitters, allowing them to stay in the brain longer."},{"drug_id":"trazodone","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Desyrel","generic_name":"trazodone","company_name":"Generic (originally Angelini/Pragmaten)","drug_phase":"marketed","molecular_target":"HLA class I histocompatibility antigen, A-3 alpha chain, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","drug_class":"SARI (Serotonin antagonist and reuptake inhibitor)","quality_score":57,"revenue":null,"mechanism":"Serotonin antagonist and reuptake inhibitor (SARI) that blocks 5-HT2A receptors and H1 receptors, used primarily as a sedative-hypnotic at low doses."},{"drug_id":"dextromethorphan","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delsym","generic_name":"dextromethorphan","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6","drug_class":"Antitussive (non-opioid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mirtazapine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remeron","generic_name":"mirtazapine","company_name":"Generic (originally Organon/MSD)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C","drug_class":"NaSSA (Noradrenergic and specific serotonergic antidepressant)","quality_score":56,"revenue":null,"mechanism":"Noradrenergic and specific serotonergic antidepressant (NaSSA) that blocks alpha-2 adrenergic, 5-HT2, 5-HT3, and H1 receptors."},{"drug_id":"effexor","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Effexor","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cital","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cital","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"wellbutrin","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Wellbutrin","company_name":"Mclean Hospital","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zelapar","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zelapar","company_name":"Baylor College of Medicine","drug_phase":"marketed","molecular_target":"Alpha-synuclein, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gepirone","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEPIRONE","company_name":"","drug_phase":"marketed","molecular_target":"5HT1A receptors","drug_class":"gepirone","quality_score":53,"revenue":null,"mechanism":"EXXUA's antidepressant effect may stem from modulating serotonergic activity via selective agonist activity at 5HT1A receptors."},{"drug_id":"elontril","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elontril","company_name":"Boehringer Ingelheim","drug_phase":"phase_3","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl894","indication_name":"Treatment of Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUPROPION","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"citalopram-hydrobromide","indication_name":"Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CITALOPRAM HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"desvenlafaxine-succinate","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DESVENLAFAXINE SUCCINATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl809","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SERTRALINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1118","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DESVENLAFAXINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"ly4064809","indication_name":"Treatment of major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ly4064809","generic_name":"ly4064809","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":32,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"reboxetine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edronax","generic_name":"REBOXETINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"reboxetine","quality_score":26,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":47,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05932407","title":"A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression","phase":"","overall_status":"COMPLETED","enrollment_count":147777,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07453420","title":"Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-phenotyping.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Shalvata Mental Health Center","has_results":false},{"nct_id":"NCT05952713","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","phase":"","overall_status":"COMPLETED","enrollment_count":73336,"lead_sponsor_name":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","has_results":false},{"nct_id":"NCT06070766","title":"RIVER At Home Ketamine Protocols","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"RIVER Foundation","has_results":false},{"nct_id":"NCT05816018","title":"Improving Health Care in Major Depressive Disorder","phase":"","overall_status":"UNKNOWN","enrollment_count":30900,"lead_sponsor_name":"Ospedale San Raffaele","has_results":false},{"nct_id":"NCT07015944","title":"Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan","phase":"NA","overall_status":"RECRUITING","enrollment_count":26376,"lead_sponsor_name":"Pakistan Institute of Living and Learning","has_results":false},{"nct_id":"NCT07281729","title":"Investigation on Risk Factors for Suicide Among Chinese Patients With Mood Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":25000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT03716869","title":"Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder","phase":"NA","overall_status":"COMPLETED","enrollment_count":12909,"lead_sponsor_name":"Milton S. Hershey Medical Center","has_results":true},{"nct_id":"NCT07305701","title":"Cohort Study on Medical Students' Mental Health","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Centre Hospitalier Régional d'Orléans","has_results":false},{"nct_id":"NCT05480150","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT06856668","title":"A Megastudy of Single-Session Interventions for Depression","phase":"NA","overall_status":"COMPLETED","enrollment_count":7505,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05541302","title":"Retrospective TMS Therapy for Adults With MDD","phase":"","overall_status":"COMPLETED","enrollment_count":6456,"lead_sponsor_name":"Neuronetics","has_results":false},{"nct_id":"NCT06512324","title":"Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5000,"lead_sponsor_name":"Biomedical Discoveries and Neuroscientific Foundations LLC","has_results":false},{"nct_id":"NCT00018057","title":"Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT03790085","title":"Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":2700,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT06332261","title":"Standardized Assessment in Depression Treatment in Routine Psychiatric Services","phase":"","overall_status":"COMPLETED","enrollment_count":2173,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05800925","title":"Triage Survey for Psychiatry Research Eligibility","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Adams Clinical","has_results":false},{"nct_id":"NCT07189689","title":"Mental Health Mission Mood Disorder Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT07212075","title":"Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups","phase":"","overall_status":"RECRUITING","enrollment_count":1809,"lead_sponsor_name":"Forschungsinstitut der Diabetes Akademie Mergentheim","has_results":false},{"nct_id":"NCT07314190","title":"Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1799,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT06628388","title":"Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong","phase":"NA","overall_status":"RECRUITING","enrollment_count":1728,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT01436175","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1570,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03864614","title":"A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1515,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05411302","title":"Augmenting Mental Health Support Through a Supportive Text Messaging Program","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Vincent Agyapong","has_results":false},{"nct_id":"NCT07239843","title":"Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1310,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT04120285","title":"Appalachian Mind Health Initiative","phase":"NA","overall_status":"COMPLETED","enrollment_count":1280,"lead_sponsor_name":"University of South Florida","has_results":false},{"nct_id":"NCT01436149","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1262,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05603104","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1254,"lead_sponsor_name":"Dr. Inge Winter","has_results":false},{"nct_id":"NCT03322774","title":"Sleep To Reduce Incident Depression Effectively","phase":"NA","overall_status":"COMPLETED","enrollment_count":1237,"lead_sponsor_name":"Henry Ford Health System","has_results":false},{"nct_id":"NCT05527951","title":"Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT01435759","title":"SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1197,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04633096","title":"The Efficacy of Automated Feedback After Internet-based Depression Screening","phase":"NA","overall_status":"COMPLETED","enrollment_count":1178,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT03538691","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1149,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT06743633","title":"Association of Beta Blocker Use with Depressive Outcomes","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1136,"lead_sponsor_name":"Chitkara University","has_results":false},{"nct_id":"NCT02371980","title":"Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1106,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT01436162","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1105,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04114565","title":"Prevalence of Major Depression Among Immigrants in Santiago, Chile","phase":"","overall_status":"COMPLETED","enrollment_count":1092,"lead_sponsor_name":"Pontificia Universidad Catolica de Chile","has_results":false},{"nct_id":"NCT01715805","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1022,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT05426265","title":"The Effects of Videogames on Depression Symptoms and Brain Dynamics","phase":"NA","overall_status":"COMPLETED","enrollment_count":1001,"lead_sponsor_name":"Aalto University","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT05819021","title":"Open Label Optimization Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Magnus Medical","has_results":false},{"nct_id":"NCT07052357","title":"Intern Health Study 2025","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT03555136","title":"Real-life Effectiveness of Vortioxetine in Depression","phase":"","overall_status":"COMPLETED","enrollment_count":992,"lead_sponsor_name":"H. Lundbeck A/S","has_results":false},{"nct_id":"NCT05547711","title":"Prediction and Validation of Unipolar Depression With Psychosocial-somatic Markers in a Naturalistic Cohort Recruited in an Outpatient Setting","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":950,"lead_sponsor_name":"Julia Eder","has_results":false},{"nct_id":"NCT05593029","title":"A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":929,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT00034983","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04209296","title":"Chart Review of Patients Undergoing Ketamine Infusions","phase":"","overall_status":"COMPLETED","enrollment_count":891,"lead_sponsor_name":"Brain and Cognition Discovery Foundation","has_results":false},{"nct_id":"NCT04039022","title":"Open-Label Safety Study of AXS-05 in Subjects With Depression","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":876,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06076317","title":"Relevance of a Telemedicine Monitoring in the Management of Depression","phase":"NA","overall_status":"RECRUITING","enrollment_count":836,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT01469377","title":"Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":819,"lead_sponsor_name":"Forest Laboratories","has_results":true}],"total":50},"guidelines":[{"drug_id":"fluoxetine","guideline_body":"FDA label","recommendation":"Fluoxetine is indicated for the acute and maintenance treatment of Major Depressive Disorder.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"fluoxetine","guideline_body":"FDA label","recommendation":"Fluoxetine is indicated for the acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD).","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"fluoxetine","guideline_body":"FDA label","recommendation":"Fluoxetine is indicated for the acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"pristiq","guideline_body":"FDA label","recommendation":"PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD).","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"sertraline","guideline_body":"FDA label","recommendation":"Sertraline hydrochloride is indicated for the treatment of major depressive disorder in adults.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sertraline","guideline_body":"FDA label","recommendation":"Sertraline hydrochloride is indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sertraline","guideline_body":"FDA label","recommendation":"Sertraline hydrochloride is indicated for the treatment of panic disorder.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sertraline","guideline_body":"FDA label","recommendation":"Sertraline hydrochloride is indicated for the treatment of posttraumatic stress disorder.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sertraline","guideline_body":"FDA label","recommendation":"Sertraline hydrochloride is indicated for the treatment of premenstrual dysphoric disorder.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sertraline","guideline_body":"FDA label","recommendation":"Sertraline hydrochloride is indicated for the treatment of social phobia.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"duloxetine","guideline_body":"FDA label","recommendation":"Duloxetine is indicated for the treatment of major depressive disorder in adults.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"mirtazapine","guideline_body":"FDA label","recommendation":"Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"effexor-xr","guideline_body":"FDA label","recommendation":"Venlafaxine hydrochloride extended-release capsules are indicated for the treatment of adults with Major Depressive Disorder.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"effexor-xr","guideline_body":"FDA label","recommendation":"Venlafaxine hydrochloride extended-release capsules are indicated for the treatment of adults with Generalized Anxiety Disorder.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"effexor-xr","guideline_body":"FDA label","recommendation":"Venlafaxine hydrochloride extended-release capsules are indicated for the treatment of adults with Social Anxiety Disorder.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"effexor-xr","guideline_body":"FDA label","recommendation":"Venlafaxine hydrochloride extended-release capsules are indicated for the treatment of adults with Panic Disorder.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"desvenlafaxine","guideline_body":"FDA label","recommendation":"PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD).","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"escitalopram","guideline_body":"FDA label","recommendation":"Escitalopram is indicated for the treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"venlafaxine","guideline_body":"FDA label","recommendation":"Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}